These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29660019)

  • 1. Modeling the diffusion of D-2-hydroxyglutarate from IDH1 mutant gliomas in the central nervous system.
    Linninger A; Hartung GA; Liu BP; Mirkov S; Tangen K; Lukas RV; Unruh D; James CD; Sarkaria JN; Horbinski C
    Neuro Oncol; 2018 Aug; 20(9):1197-1206. PubMed ID: 29660019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
    Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
    Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 and seizures in patients with glioma.
    Chen H; Judkins J; Thomas C; Wu M; Khoury L; Benjamin CG; Pacione D; Golfinos JG; Kumthekar P; Ghamsari F; Chen L; Lein P; Chetkovich DM; Snuderl M; Horbinski C
    Neurology; 2017 May; 88(19):1805-1813. PubMed ID: 28404805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma.
    Molloy AR; Najac C; Viswanath P; Lakhani A; Subramani E; Batsios G; Radoul M; Gillespie AM; Pieper RO; Ronen SM
    Theranostics; 2020; 10(19):8757-8770. PubMed ID: 32754276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
    Pope WB; Prins RM; Albert Thomas M; Nagarajan R; Yen KE; Bittinger MA; Salamon N; Chou AP; Yong WH; Soto H; Wilson N; Driggers E; Jang HG; Su SM; Schenkein DP; Lai A; Cloughesy TF; Kornblum HI; Wu H; Fantin VR; Liau LM
    J Neurooncol; 2012 Mar; 107(1):197-205. PubMed ID: 22015945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation.
    Pianka ST; Li T; Prins TJ; Eldred BSC; Kevan BM; Liang H; Zapanta Rinonos S; Kornblum HI; Nathanson DA; Pellegrini M; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    Cancer Res Commun; 2024 Mar; 4(3):876-894. PubMed ID: 38445960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways.
    Fack F; Tardito S; Hochart G; Oudin A; Zheng L; Fritah S; Golebiewska A; Nazarov PV; Bernard A; Hau AC; Keunen O; Leenders W; Lund-Johansen M; Stauber J; Gottlieb E; Bjerkvig R; Niclou SP
    EMBO Mol Med; 2017 Dec; 9(12):1681-1695. PubMed ID: 29054837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
    Balss J; Pusch S; Beck AC; Herold-Mende C; Krämer A; Thiede C; Buckel W; Langhans CD; Okun JG; von Deimling A
    Acta Neuropathol; 2012 Dec; 124(6):883-91. PubMed ID: 23117877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma.
    Chen X; Liu J; Li Y; Zeng Y; Wang F; Cheng Z; Duan H; Pan G; Yang S; Chen Y; Li Q; Shen X; Li Y; Qin Z; Chen J; Huang Y; Wang X; Lu Y; Shu M; Zhang Y; Wang G; Li K; Lin X; Xing F; Zhang H
    Nat Commun; 2023 Oct; 14(1):6781. PubMed ID: 37880243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
    Avellaneda Matteo D; Grunseth AJ; Gonzalez ER; Anselmo SL; Kennedy MA; Moman P; Scott DA; Hoang A; Sohl CD
    J Biol Chem; 2017 May; 292(19):7971-7983. PubMed ID: 28330869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function.
    Sasaki M; Knobbe CB; Itsumi M; Elia AJ; Harris IS; Chio II; Cairns RA; McCracken S; Wakeham A; Haight J; Ten AY; Snow B; Ueda T; Inoue S; Yamamoto K; Ko M; Rao A; Yen KE; Su SM; Mak TW
    Genes Dev; 2012 Sep; 26(18):2038-49. PubMed ID: 22925884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas.
    Ohno M; Hayashi Y; Aikawa H; Hayashi M; Miyakita Y; Takahashi M; Matsushita Y; Yoshida A; Satomi K; Ichimura K; Hamada A; Narita Y
    Neurology; 2021 Nov; 97(21):e2114-e2123. PubMed ID: 34610989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimally Invasive Detection of IDH1 Mutation With Cell-Free Circulating Tumor DNA and D-2-Hydroxyglutarate, D/L-2-Hydroxyglutarate Ratio in Gliomas.
    Tuna G; Dal-Bekar NE; Akay A; Rükşen M; İşlekel S; İşlekel GH
    J Neuropathol Exp Neurol; 2022 Jun; 81(7):502-510. PubMed ID: 35582888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
    Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas.
    Jin G; Reitman ZJ; Duncan CG; Spasojevic I; Gooden DM; Rasheed BA; Yang R; Lopez GY; He Y; McLendon RE; Bigner DD; Yan H
    Cancer Res; 2013 Jan; 73(2):496-501. PubMed ID: 23204232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nuclear FABP7 regulates cell proliferation of wild-type IDH1 glioma through caveolae formation.
    Kagawa Y; Umaru BA; Kanamori M; Zama R; Shil SK; Miyazaki H; Kobayashi S; Wannakul T; Yang S; Tominaga T; Owada Y
    Mol Oncol; 2022 Jan; 16(1):289-306. PubMed ID: 34716958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.